Viatris Inc.
VTRS Large CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Viatris Inc. en bref
Viatris Inc. (VTRS) is currently trading at 13,41 € with a market capitalization of 15,6 Md €. The 52-week range spans from 7,53 € to 15,30 €; the current price is 12.3% below the yearly high. Year-over-year revenue growth stands at +8.1%.
💰 Dividende
Viatris Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
8 analystes évaluent Viatris Inc. (VTRS) au consensus : Acheter. L'objectif de cours moyen est de 15,54 €, soit un potentiel de +15.89% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 10,47 € à 20,07 €.
Viatris Inc. : la thèse d'investissement en détail
Viatris Inc. (VTRS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Buy with an average price target implying roughly 15.89% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Valorisation en contexte
With a PEG ratio of 0.15, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.49x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Free cash flow positif
- –Actuellement non rentable
Aperçu technique
Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Viatris Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
